Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Experience Is a Gloomy Lantern That Does Not Even Illuminate Its Bearer

Experience Is a Gloomy Lantern That Does Not Even Illuminate Its Bearer Steinman1 stressed that millions of people were early adopters of rofecoxib (Vioxx; Merck Co) and rosiglitazone (Avandia; GlaxoSmithKline), which were withdrawn or restricted for severe safety concerns. Accordingly, the findings of Schwartz and Woloshin2 are very surprising. They showed evidence that a substantial proportion of the public mistakenly believes that the Food and Drug Administration approves only extremely effective drugs and drugs lacking serious adverse effects.2 This deserves 2 questions. What is the proportion of health care professionals who have similar misconceptions? The editor seems to think it is high because she published a piece to remind us of very basic principles.3 When will direct-to-consumer advertising (DTCA) be banned? It is time to close this Pandora's box opened in 1997. Indeed, spending on DTCA for prescription drugs in the United States has increased dramatically over the last decade, and the flow on the Internet is out of control.4 Moreover, clinicians are not receptive to questions arising from DTCA.5 Back to top Article Information Correspondence: Dr Braillon, Department of Public Health, Gres, 27 rue Voiture, Amiens 80000, France (braillon.alain@gmail.com). Financial Disclosure: None reported. References 1. Steinman MA. Using patients to promote evidence-based prescribing. Arch Intern Med. 2011;171(16):1468-146921911630PubMedGoogle ScholarCrossref 2. Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public: a national randomized trial. Arch Intern Med. 2011;171(16):1463-146821911629PubMedGoogle ScholarCrossref 3. Schiff GD, Galanter WL, Duhig J, Lodolce AE, Koronkowski MJ, Lambert BL. Principles of conservative prescribing. Arch Intern Med. 2011;171(16):1433-144021670331PubMedGoogle ScholarCrossref 4. Weppner WG, Hollon MF, Chew LD, Larson EB. Direct-to-consumer offers for free and discounted medications on the internet: a content analysis of “e-samples.” Arch Intern Med. 2009;169(21):2024-203019933966PubMedGoogle ScholarCrossref 5. Zachry WM III, Dalen JE, Jackson TR. Clinicians' responses to direct-to-consumer advertising of prescription medications. Arch Intern Med. 2003;163(15):1808-181212912716PubMedGoogle ScholarCrossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Experience Is a Gloomy Lantern That Does Not Even Illuminate Its Bearer

Braillon, Alain
Archives of Internal Medicine , Volume 172 (3) – Feb 13, 2012
Download PDF
1 page

Experience Is a Gloomy Lantern That Does Not Even Illuminate Its Bearer

Abstract

Steinman1 stressed that millions of people were early adopters of rofecoxib (Vioxx; Merck Co) and rosiglitazone (Avandia; GlaxoSmithKline), which were withdrawn or restricted for severe safety concerns. Accordingly, the findings of Schwartz and Woloshin2 are very surprising. They showed evidence that a substantial proportion of the public mistakenly believes that the Food and Drug Administration approves only extremely effective drugs and drugs lacking serious adverse effects.2 This deserves...
Loading next page...
 
/lp/american-medical-association/experience-is-a-gloomy-lantern-that-does-not-even-illuminate-its-CC60O4R3OX

References (7)

Publisher
American Medical Association
Copyright
Copyright © 2012 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinternmed.2011.760
Publisher site
See Article on Publisher Site

Abstract

Steinman1 stressed that millions of people were early adopters of rofecoxib (Vioxx; Merck Co) and rosiglitazone (Avandia; GlaxoSmithKline), which were withdrawn or restricted for severe safety concerns. Accordingly, the findings of Schwartz and Woloshin2 are very surprising. They showed evidence that a substantial proportion of the public mistakenly believes that the Food and Drug Administration approves only extremely effective drugs and drugs lacking serious adverse effects.2 This deserves 2 questions. What is the proportion of health care professionals who have similar misconceptions? The editor seems to think it is high because she published a piece to remind us of very basic principles.3 When will direct-to-consumer advertising (DTCA) be banned? It is time to close this Pandora's box opened in 1997. Indeed, spending on DTCA for prescription drugs in the United States has increased dramatically over the last decade, and the flow on the Internet is out of control.4 Moreover, clinicians are not receptive to questions arising from DTCA.5 Back to top Article Information Correspondence: Dr Braillon, Department of Public Health, Gres, 27 rue Voiture, Amiens 80000, France (braillon.alain@gmail.com). Financial Disclosure: None reported. References 1. Steinman MA. Using patients to promote evidence-based prescribing. Arch Intern Med. 2011;171(16):1468-146921911630PubMedGoogle ScholarCrossref 2. Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public: a national randomized trial. Arch Intern Med. 2011;171(16):1463-146821911629PubMedGoogle ScholarCrossref 3. Schiff GD, Galanter WL, Duhig J, Lodolce AE, Koronkowski MJ, Lambert BL. Principles of conservative prescribing. Arch Intern Med. 2011;171(16):1433-144021670331PubMedGoogle ScholarCrossref 4. Weppner WG, Hollon MF, Chew LD, Larson EB. Direct-to-consumer offers for free and discounted medications on the internet: a content analysis of “e-samples.” Arch Intern Med. 2009;169(21):2024-203019933966PubMedGoogle ScholarCrossref 5. Zachry WM III, Dalen JE, Jackson TR. Clinicians' responses to direct-to-consumer advertising of prescription medications. Arch Intern Med. 2003;163(15):1808-181212912716PubMedGoogle ScholarCrossref

Journal

Archives of Internal Medicine – American Medical Association

Published: Feb 13, 2012

Keywords: rosiglitazone,health personnel,internet,prescriptions, drug,rofecoxib,prescription drug,adverse effects

There are no references for this article.